의료기기관련기관/국가임상시험지원재단
해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 3.28.(목)
toucrew
2024. 9. 15. 09:10
반응형
| 보고서 (영문) | |
| 제약/바이오/ 임상시험 |
Janssen Gains Approval for Rybrevant as First-Line Treatment for NSCLC Subtype |
| Innovent’s ROS1 TKI Is One Step Closer to Winning the Chinese NSCLC Market | |
| FLOW Trial Sheds Positive Light on Ozempic for CKD | |
| GLP1 Agonists to Surpass PD1 Antagonists as the Best Selling Drugs in 2024 and Beyond | |
| IO360: Phase II Trial Reveals Motixafortide's Efficacy in First-Line Pancreatic Cancer Treatment | |
| RNA-Based Drugs and the Impact of COVID-19 | |
| Eli Lilly’s Partnership with Amazon to Boost Presence in Diabetes and Obesity Markets | |
| Padcev, Keytruda, and Balversa Leave Little Room for Opdivo in Urothelial Carcinoma | |
| 질환별 | Polycystic Ovarian Syndrome: Competitive Landscape |
| Cases of Tuberculosis Could Exceed Pre-Pandemic Numbers in England | |
| TB Potentially Transmissible in Undiagnosed Cases | |
| Cell & Gene Therapies in CNS Disorders | |
| Artificial Intelligence Identified Two Evolutionary Pathways of Prostate Cancer | |
| Female Vitiligo Patients Are at an Increased Risk of Osteoporosis | |
| Lung Cancer Deaths Have Declined Sharply in UK Middle-Aged Adults | |
| 컨퍼런스/ 심포지엄/ 학회/기타 |
AD/PD 2024: Early Diagnosis Remains a Hurdle for DMT in Parkinson’s |
| AD/PD 2024: The Role of Blood-Based Biomarkers in Alzheimer’s Disease | |
| AD/PD 2024: Promise for TauRx’s HMTM, Despite Lacking Primary Endpoint Data | |
| AD/PD 2024: Cell Therapies Show Promise for Parkinson’s Disease Non-motor Symptoms | |
| AD/PD 2024: Eli Lilly’s Donanemab Hit with FDA Delay | |
| AD/PD 2024: Leqembi Data Supports Early Treatment Initiation for Better Outcomes | |
| AD/PD 2024: BioVie’s Novel NE3107 Shows Promise but Confirmatory Trial Needed | |
| AD/PD 2024: Exploring Cutting-Edge Therapies for Amyotrophic Lateral Sclerosis | |
| Defining the HTA Landscape for France and Germany: 2019–23 | |
| Highlights from the IO360 Conference: PD-1 Inhibitors and Systemic Oncolytic Viral Immunotherapies | |
| New NIH Cancer Screening Research Network to Evaluate Screening Technologies | |
| BIOSECURE Act Could Impact WuXi-Manufactured Drugs for the US Market | |
| Clinical Trial Decline Highlights a Lack of Incentives for Drug Manufacturers |
반응형